Form 4: Calidi Biotherapeutics Director Buys Shares & Warrants

Calidi Biotherapeutics Director Scott Leftwich acquired 125,000 shares of common stock and 125,000 warrants in a public offering, increasing his direct beneficial ownership.

Summary

• Director Scott Leftwich acquired 125,000 shares of Calidi Biotherapeutics common stock.
• He also acquired 125,000 warrants, each exercisable at $2.00, expiring on August 21, 2030.
• The acquisition occurred on August 21, 2025, as part of a public offering conducted by the Issuer.
• Each common share was purchased with an accompanying warrant for a combined price of $2.00.
• Following the transaction, Mr. Leftwich directly beneficially owns 130,650 shares of common stock and 125,000 warrants.
• He also indirectly beneficially owns 14,672 shares through SECBL, LLC and 1,309 shares through WEBCL, LLC, where he serves as the managing member.

Sentiment

Score: 8

Explanation: The acquisition of a substantial number of shares and warrants by a director in a public offering is a strong positive signal, indicating high confidence in the company's future and aligning insider interests with shareholders. The future transaction date is unusual but does not detract from the positive sentiment of the insider buy itself.

Positives

• A director's purchase of a significant number of shares and warrants in a public offering demonstrates strong confidence in the company's future prospects.
• Increased insider ownership aligns management's interests with those of shareholders, which is generally viewed favorably by the market.
• The acquisition was part of a public offering, indicating the company successfully raised capital.

Negatives

• No specific negative information is disclosed in this Form 4 filing.

Risks

• This Form 4 filing does not detail specific risks related to the company's operations or financial health.

Future Outlook

This Form 4 filing does not provide specific forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

Insider buying, particularly by a director, can be viewed positively by the market, suggesting confidence in the company's strategy and future within the biotherapeutics sector. While this filing does not provide broader industry trends, such an action by a director in a public offering could signal a belief in the company's ability to execute its pipeline or market strategy.

Comparison to Industry Standards

• NA

Related Party Transactions

• The reporting person, Scott Leftwich, is the managing member of SECBL, LLC and WEBCL, LLC, through which he indirectly beneficially owns additional common stock. This relationship is disclosed as part of his beneficial ownership reporting.

Stakeholder Impact

• Shareholders: The purchase by a director can instill confidence among existing and potential shareholders, suggesting a belief in the company's value and future growth.
• Employees: While not directly impacted, a strong signal of confidence from leadership can indirectly boost morale.
• Creditors/Lenders: Positive insider sentiment might be viewed favorably, indicating stability and future potential, though this filing has no direct impact on creditworthiness.

Next Steps

• This filing does not explicitly mention future actions or milestones beyond the transaction itself. Investors will likely monitor future SEC filings for further insider activity or company operational updates.

Key Dates

Recommendation

The significant purchase of common stock and warrants by a director in a public offering signals strong insider confidence in Calidi Biotherapeutics' future. Such an action, especially at a set price, suggests management believes the stock is undervalued or has substantial upside potential. This alignment of interests typically serves as a positive indicator for investors, warranting a 'buy' recommendation based on this insider activity.

Keywords

Calidi Biotherapeutics, CLDI, Scott Leftwich, Insider Buying, Form 4, Public Offering, Warrants, Common Stock, Director Purchase, Biotherapeutics